Haemonetics stock heads toward its November 5 results
Published on 10/07/2026 at 02:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Haemonetics Corporation (ISIN US4050241003) closed at USD 104.85 on the NYSE on October 5, 2026, while the company heads toward its next scheduled results date. Haemonetics will publish second-quarter fiscal 2027 figures on November 5, 2026, at 6:00 a.m. ET, followed by an analyst call at 8:00 a.m. ET, according to Haemonetics.
November 5 sets the next test
The upcoming report follows fiscal first-quarter revenue of USD 339.38 million for the quarter ended June 27, 2026. That result was 5.5 percent above the prior-year quarter and exceeded the USD 327.86 million analyst estimate, according to MarketBeat. The comparison gives the November release a clear operating benchmark: investors will be looking for further growth after a revenue beat.
Adjusted earnings per share reached USD 1.14 in fiscal Q1 2027, above the USD 1.08 consensus estimate and up from USD 1.10 in the year-earlier quarter. Benzinga reported that management raised fiscal 2027 reported revenue growth guidance to 5 percent to 8 percent and organic growth guidance to 4 percent to 7 percent.
Analysts see limited upside
The analyst picture is constructive but not uniform. MarketBeat described a Moderate Buy consensus from 11 brokerages, including six buys, four holds and one strong buy, with an average 12-month target of USD 99.78. That average sits USD 5.07 below the October 5 closing price, a difference of 4.8 percent.
Recent individual actions point in the other direction. According to Markets Insider, Citi upgraded Haemonetics from Neutral to Buy on September 17, 2026, and set a USD 123 price target, up from USD 92. The target lies 17.3 percent above the October 5 closing price.
Stock remains near its yearly high
Haemonetics' October 5 closing price was 5.1 percent below its 52-week high of USD 110.45 and 117.8 percent above its 52-week low of USD 48.17. The company had a market capitalization of USD 4.77 billion and trading volume of 652,646 shares on that quote page.
The valuation leaves the November report as the next measurable checkpoint. Revenue growth, adjusted EPS and the guidance range will show whether the premium valuation is supported by continued execution in plasma collection and blood-management technologies.
Haemonetics stock closes at USD 104.85
Haemonetics stock closed at USD 104.85 on the NYSE on October 5, 2026, with a daily gain of 0.17 percent. The next scheduled results date is November 5, 2026.
Haemonetics stock facts
- Company: Haemonetics Corporation
- ISIN: US4050241003
- Ticker: HAE
- Trading venue: NYSE
- Price (as of October 5, 2026, 3:59 p.m. ET): USD 104.85, Closing price (October 5, 2026)
- Market capitalization: USD 4.77 billion (as of October 5, 2026)
- 52-week range: USD 48.17-110.45 (as of October 5, 2026)
- Sector / Industry: Healthcare / Healthcare Equipment and Supplies
Upcoming dates for Haemonetics stock
- November 5, 2026: Second-quarter fiscal 2027 results
